JP2011526891A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011526891A5 JP2011526891A5 JP2011516335A JP2011516335A JP2011526891A5 JP 2011526891 A5 JP2011526891 A5 JP 2011526891A5 JP 2011516335 A JP2011516335 A JP 2011516335A JP 2011516335 A JP2011516335 A JP 2011516335A JP 2011526891 A5 JP2011526891 A5 JP 2011526891A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- fusion protein
- protein
- trail
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000037865 fusion proteins Human genes 0.000 claims description 24
- 108020001507 fusion proteins Proteins 0.000 claims description 24
- 229920001184 polypeptide Polymers 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 208000023275 Autoimmune disease Diseases 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 101100046559 Mus musculus Tnfrsf12a gene Proteins 0.000 claims description 5
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 claims description 5
- 108700012411 TNFSF10 Proteins 0.000 claims description 5
- 102100024584 Tumor necrosis factor ligand superfamily member 12 Human genes 0.000 claims description 5
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 claims description 4
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 101000830565 Homo sapiens Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 claims description 2
- 101000648505 Homo sapiens Tumor necrosis factor receptor superfamily member 12A Proteins 0.000 claims description 2
- 102000055458 human TNFRSF12A Human genes 0.000 claims description 2
- 102000044949 human TNFSF10 Human genes 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 101710097155 Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 11
- 201000011510 cancer Diseases 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 4
- 108010039471 Fas Ligand Protein Proteins 0.000 description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101150026580 CD5 gene Proteins 0.000 description 1
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 description 1
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000981093 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 1 Proteins 0.000 description 1
- 101000650817 Homo sapiens Semaphorin-4D Proteins 0.000 description 1
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101100166612 Mus musculus Cd72 gene Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- -1 PDL-2 Proteins 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13353208P | 2008-06-30 | 2008-06-30 | |
| US61/133,532 | 2008-06-30 | ||
| PCT/US2009/003886 WO2010005519A1 (en) | 2008-06-30 | 2009-06-30 | Fn14/trail fusion proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011526891A JP2011526891A (ja) | 2011-10-20 |
| JP2011526891A5 true JP2011526891A5 (enExample) | 2012-08-16 |
| JP5475766B2 JP5475766B2 (ja) | 2014-04-16 |
Family
ID=41278748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011516335A Active JP5475766B2 (ja) | 2008-06-30 | 2009-06-30 | Ｆｎ１４／ＴＲＡＩＬ融合タンパク質 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US8039437B2 (enExample) |
| EP (2) | EP2297198B1 (enExample) |
| JP (1) | JP5475766B2 (enExample) |
| CN (1) | CN102137869B (enExample) |
| AU (1) | AU2009269141B2 (enExample) |
| CA (1) | CA2729351C (enExample) |
| IL (1) | IL210175A0 (enExample) |
| SG (1) | SG191698A1 (enExample) |
| WO (1) | WO2010005519A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5947727B2 (ja) | 2010-01-20 | 2016-07-06 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片による免疫調節 |
| US9023997B2 (en) | 2010-01-20 | 2015-05-05 | Merck Sharp & Dohme Corp. | Anti-ILT5 antibodies and ILT5-binding antibody fragments |
| PL391627A1 (pl) * | 2010-06-25 | 2012-01-02 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Przeciwnowotworowe białko fuzyjne |
| WO2012042480A1 (en) | 2010-09-28 | 2012-04-05 | Kahr Medical Ltd. | Compositions and methods for treatment of hematological malignancies |
| PL219845B1 (pl) * | 2011-01-05 | 2015-07-31 | Adamed Spółka Z Ograniczoną Odpowiedzialnością | Przeciwnowotworowe białko fuzyjne |
| CN102206281B (zh) * | 2011-03-28 | 2014-04-09 | 中国人民解放军第三军医大学第一附属医院 | 融合蛋白tetph、表达载体及其构建方法 |
| WO2012145568A1 (en) | 2011-04-21 | 2012-10-26 | Albert Einstein College Of Medicine Of Yeshiva University | Antibodies to human b7x for treatment of metastatic cancer |
| PL397167A1 (pl) * | 2011-11-28 | 2013-06-10 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Przeciwnowotworowe bialko fuzyjne |
| WO2014121093A1 (en) | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Fusion proteins that facilitate cancer cell destruction |
| WO2014121099A1 (en) | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Agonist fusion protein for cd40 ox40 and uses thereof |
| WO2014121085A1 (en) * | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Pd-l1 and pd-l2-based fusion proteins and uses thereof |
| US9797882B2 (en) | 2013-07-09 | 2017-10-24 | The Translational Genomics Research Institute | Method of screening for a compound for inhibitory activity of FN14-tweak interaction |
| WO2015006508A2 (en) * | 2013-07-09 | 2015-01-15 | The Translational Genomics Research Institute | Compositions and methods of screening for compounds that modulate activity at a tweak binding site on a crd of fn14 |
| US11111284B2 (en) | 2014-08-21 | 2021-09-07 | The General Hospital Corporation | Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing |
| WO2016139668A2 (en) * | 2015-03-03 | 2016-09-09 | Kahr Medical (2005) Ltd | Dual signaling protein (dsp) fusion proteins, and methods of using thereof for treating diseases |
| RU2766200C1 (ru) | 2015-10-01 | 2022-02-09 | Хит Байолоджикс, Инк. | Композиции и способы для соединения внеклеточных доменов типа i и типа ii в качестве гетерологичных химерных белков |
| AU2018205888B2 (en) | 2017-01-05 | 2021-09-02 | Kahr Medical Ltd. | A PD1-41BBL fusion protein and methods of use thereof |
| US11299530B2 (en) | 2017-01-05 | 2022-04-12 | Kahr Medical Ltd. | SIRP alpha-CD70 fusion protein and methods of use thereof |
| SI3565828T1 (sl) | 2017-01-05 | 2022-04-29 | Kahr Medical Ltd. | SIRP1 alfa-41BBL fuzijski protein in postopki za njegovo uporabo |
| US11566060B2 (en) | 2017-01-05 | 2023-01-31 | Kahr Medical Ltd. | PD1-CD70 fusion protein and methods of use thereof |
| KR102745835B1 (ko) | 2017-02-27 | 2024-12-24 | 샤턱 랩스 인코포레이티드 | Tigit- 및 light-기반 키메라 단백질 |
| CA3054132A1 (en) | 2017-02-27 | 2018-08-30 | Shattuck Labs, Inc. | Csf1r-based chimeric proteins |
| CN118184797A (zh) | 2017-02-27 | 2024-06-14 | 沙塔克实验室有限公司 | 基于vsig8的嵌合蛋白 |
| CN118852460A (zh) * | 2017-12-28 | 2024-10-29 | 尤利乌斯·马克西米利安维尔茨堡大学 | 具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白；TRAAFFIAA) |
| US12286466B2 (en) | 2018-07-11 | 2025-04-29 | Kahr Medical Ltd. | PD1-4-1BBL variant fusion protein and methods of use thereof |
| CA3104780A1 (en) | 2018-07-11 | 2020-01-16 | Kahr Medical Ltd. | Sirpalpha-4-1bbl variant fusion protein and methods of use thereof |
| US10780121B2 (en) | 2018-08-29 | 2020-09-22 | Shattuck Labs, Inc. | FLT3L-based chimeric proteins |
| WO2021005599A1 (en) | 2019-07-11 | 2021-01-14 | Kahr Medical Ltd. | Heterodimers and methods of use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
| US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
| EP2298333A3 (en) * | 1999-12-20 | 2012-05-02 | Immunex Corporation | Tweak receptor |
| US7208151B2 (en) * | 2001-09-12 | 2007-04-24 | Biogen Idec Ma Inc. | Tweak receptor agonists as anti-angiogenic agents |
| US7378089B2 (en) * | 2001-10-02 | 2008-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Gene therapy for the prevention of autoimmune disease |
| CN103536916B (zh) * | 2002-04-09 | 2016-08-17 | 比奥根Ma公司 | 用于治疗tweak相关病症的方法 |
| JP4690044B2 (ja) * | 2002-10-29 | 2011-06-01 | アナフォア インコーポレイテッド | ３量体サイトカイン用の３量体結合タンパク質 |
| WO2005010045A1 (en) * | 2003-07-24 | 2005-02-03 | Amgen Inc. | Compositions and methods relating to multimeric and oligomeric soluble fragments of the tweak receptor |
| US7285522B2 (en) * | 2004-08-25 | 2007-10-23 | The Clorox Company | Bleaching with improved whitening |
-
2009
- 2009-06-30 JP JP2011516335A patent/JP5475766B2/ja active Active
- 2009-06-30 US US12/494,680 patent/US8039437B2/en active Active
- 2009-06-30 SG SG2013049333A patent/SG191698A1/en unknown
- 2009-06-30 WO PCT/US2009/003886 patent/WO2010005519A1/en not_active Ceased
- 2009-06-30 EP EP09788855.6A patent/EP2297198B1/en active Active
- 2009-06-30 CA CA2729351A patent/CA2729351C/en active Active
- 2009-06-30 CN CN200980133865.2A patent/CN102137869B/zh active Active
- 2009-06-30 AU AU2009269141A patent/AU2009269141B2/en active Active
- 2009-06-30 EP EP12001349A patent/EP2460827A1/en not_active Ceased
-
2010
- 2010-12-22 IL IL210175A patent/IL210175A0/en active IP Right Grant
-
2011
- 2011-08-11 US US13/208,091 patent/US8329657B2/en active Active
-
2012
- 2012-08-15 US US13/586,479 patent/US20130065815A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011526891A5 (enExample) | ||
| US11357826B2 (en) | IL-10 EGFR antibody fusion protein and uses thereof | |
| CN115087464B (zh) | 新型白介素-15(il-15)融合蛋白及其用途 | |
| EP3638700B1 (en) | Proteinaceous heterodimer and use thereof | |
| CN112584851B (zh) | 新型白介素-15(il-15)融合蛋白及其用途 | |
| Kim et al. | 4-1BB: A promising target for cancer immunotherapy | |
| RU2644243C2 (ru) | Химерные антигенные рецепторы к cd22 | |
| TWI826358B (zh) | 用於治療肌肉萎縮和骨疾病的新型雜合ａｃｔｒｉｉｂ配體陷阱蛋白及其用途與生產方法 | |
| KR102128966B1 (ko) | 종양 투과성 펩타이드와 항-신생혈관생성 제제가 융합된 융합단백질을 유효성분으로 포함하는 암 또는 혈관신생관련 질환 예방 및 치료용 약학적 조성물 | |
| US20200087377A1 (en) | Multifunctional Fusion Protein and Applications Thereof | |
| JP2020506727A5 (enExample) | ||
| JP2010539236A5 (enExample) | ||
| JP2019505564A (ja) | 抗ｂｃｍａポリペプチド及びタンパク質 | |
| EP2912061A1 (en) | M971 chimeric antigen receptors | |
| EP3097123A1 (en) | Anti-ny-br-1 polypeptides, proteins, and chimeric antigen receptors | |
| KR20180030898A (ko) | Gdf15의 활성 감소용 제제 | |
| WO2018213612A1 (en) | Anti-mesothelin polypeptides and proteins | |
| CN100549175C (zh) | 一种具有抑癌作用的重组蛋白及其编码基因与应用 | |
| JP6887944B2 (ja) | 抗ｆｇｆｒ２抗体と他剤を含む組成物 | |
| US20230391863A1 (en) | Bifunctional antagonists of activin and tumor necrosis factor alpha and uses thereof | |
| WO2019204402A1 (en) | Compositions and methods for treatment of cancer | |
| JP2025531805A (ja) | 新規のｐｄ１標的化ｉｌ－１５免疫サイトカインおよびｖｉｔｏｋｉｎｅ融合物 | |
| CA3196077A1 (en) | Bifunctional antagonists of tumor necrosis factor-alpha and transforming growth factor-beta and uses thereof | |
| CN116635059A (zh) | 激活蛋白和肿瘤坏死因子-α的双功能拮抗剂及其用途 | |
| CN120390653A (zh) | Cd47阻断剂及抗bcma/抗cd3双特异性抗体的组合疗法 |